Company code: Shanghai Haoyuan Chemexpress Co.Ltd(688131) company abbreviation: Shanghai Haoyuan Chemexpress Co.Ltd(688131) Shanghai Haoyuan Chemexpress Co.Ltd(688131)
Summary of annual report 2021
Section I important tips
1 the summary of this annual report comes from the full text of the annual report. In order to fully understand the company’s operating results, financial status and future development plan, investors should http://www.sse.com.cn./ The website carefully reads the full text of the annual report. 2 major risk tips
The company has described in detail various risks and countermeasures that the company may face in the process of production and operation in this report. Please refer to “IV. risk factors” in “section III Management Discussion and analysis”. Investors are kindly requested to pay attention and pay attention to investment risks. 3 the board of directors, the board of supervisors and the directors, supervisors and senior managers of the company guarantee the authenticity, accuracy and completeness of the contents of the annual report, and there are no false records, misleading statements or major omissions, and bear individual and joint legal liabilities. 4. All directors of the company attended the board meeting. 5 Rongcheng Certified Public Accountants (special general partnership) issued a standard unqualified audit report for the company. 6. The company is not profitable and has not yet achieved profitability when it is listed □ yes √ No 7. The profit distribution plan or the plan for the conversion of provident fund into share capital in the reporting period adopted by the resolution of the board of directors
According to the strategic planning and business development needs, and on the premise of ensuring the normal capital needs of the company, the company plans to distribute a cash dividend of 5.30 yuan (including tax) to all shareholders for every 10 shares. Based on the total share capital of 74342007 shares as of December 31, 2021, the total cash dividend to be distributed is 3940126371 yuan (including tax). The proportion of cash dividends of the company in this year accounts for 20.63% of the net profit attributable to the shareholders of the company. At the same time, the company plans to increase 4 shares for every 10 shares to all shareholders with capital reserve. Based on the total share capital of 74342007 shares as of December 31, 2021, a total of 29736802 shares will be increased. After the increase, the total share capital of the company will be increased to 104078809 shares. The number of converted shares is the company’s rounding income according to the actual calculation results. The final number of converted shares is subject to the number of shares disclosed in the announcement on the implementation of equity distribution issued separately after the company has completed the legal procedures. 8. Whether there are important matters such as special arrangements for corporate governance □ applicable √ not applicable
Section II basic information of the company
1 company profile company stock profile √ applicable □ not applicable
Company stock profile
Stock type stock exchange stock abbreviation before stock code change stock abbreviation and sector
A-share Shanghai Stock Exchange Shanghai Haoyuan Chemexpress Co.Ltd(688131) Shanghai Haoyuan Chemexpress Co.Ltd(688131) not applicable
Scientific innovation board
Profile of the company’s depositary receipts □ applicable √ not applicable contact person and contact information
Contact person and contact information secretary of the board of directors (domestic representative of information disclosure) securities affairs representative
Name: Shen Weihong, Li Wenjing
Office address: Building 3, Lane 1999, zhangheng Road, Pudong New Area, Shanghai Building 3, Lane 1999, zhangheng Road, Pudong New Area, Shanghai
Tel: 02158338205
E-mail [email protected]. [email protected].
2. Introduction to the company’s main business in the reporting period (I) main business, main products or services
Shanghai Haoyuan Chemexpress Co.Ltd(688131) is a platform high-tech enterprise focusing on the R & D service and industrial application of small molecule drugs. Its main business includes the R & D of molecular blocks and tool compounds in the field of small molecule drug discovery, as well as the process development and production technology improvement of small molecule drug APIs and intermediates, Provide global pharmaceutical enterprises and scientific research institutions with relevant products and technical services from drug discovery to large-scale production of APIs and pharmaceutical intermediates.
The specific business contents, application fields and corresponding business forms are as follows:
Application fields and business forms of business content products and technologies
Molecular block and tool compound drug discovery research stage, including disease mechanism research and target product sales
Cro service discovery, lead compound and candidate compound discovery technology service
Preclinical, clinical research and commercial production of new drugs created by raw materials and intermediates; Product sales
CMC, cdmo services, generic drug application and technical services in commercial production stage
1. Molecular building blocks and tool compounds
Molecular blocks refer to small molecular compounds used to design and construct drug active substances, and tool compounds refer to small molecular compounds with biological activity, physiological function and potential drug formation. Molecular building blocks and tool compounds mainly provide mg to kg products and technical services in the drug discovery stage, including disease mechanism research, target discovery, lead compound and candidate compound discovery. The company has a comprehensive talent team with a combination of pharmaceutical, chemical, biological and computer backgrounds, has an in-depth understanding of pharmaceutical professional knowledge such as compound structure, compound synthesis, compound medicinal and chemical properties, protein structure, compound and protein binding model, and continues to pay attention to the cutting-edge trends and development trends in drug R & D fields such as disease target research. Relying on the professional understanding of pharmaceutical chemistry and synthetic chemistry, adhering to the combination of independent development and customized synthesis, we have completed a large number of laboratory synthesis and process optimization tests of compounds.
By the end of the reporting period, the company had accumulated more than 58600 kinds of molecular blocks and tool compounds, including about 42000 kinds of molecular blocks and 16000 kinds of tool compounds, and built more than 110 kinds of integrated compound libraries. Among them, there are more than 14000 kinds of self synthesized molecular blocks and tool compounds. In 2021, the company also actively arranged the business related to the biological section, and further expanded the R & D and production capacity of the front-end molecular block and tool compound business.
2. APIs and pharmaceutical intermediates
API and intermediate business mainly corresponds to pre clinical and post clinical cdmo services, as well as synthetic process development, process optimization and API registration and declaration services, and provides 100kg to ton API and intermediate products required for drug marketing and commercialization. As the effective active ingredient of drugs, API carries most of the core technologies of drug production; The supply of highly difficult APIs and intermediates is the bottleneck of drug development and production. Combined with the market and customer needs and the professional judgment of the company’s team, the company takes the potential products in molecular blocks and tool compounds as the reserves of pharmaceutical intermediates and API projects for in-depth development. With the support of excellent technological innovation ability and R & D achievement transformation ability, the company carries out process development, process optimization and quality research through perfect process R & D system, quality management system and quality control system, Form commercial products and services with market competitiveness, so as to meet customer needs with high efficiency and high quality.
By the end of this report, more than 100 kinds of API and intermediate products have been developed by the company, including 92 products that have the industrialization foundation. The products cover anti-cancer, antiviral, diabetes, cardiovascular and cerebrovascular diseases and other fields. The company’s representative API and intermediate products include iribrin, trobetadine, ADC products, baloxavir, teigliptin, tigrelol, apixaban, etc.
By the end of the reporting period, the correspondence between the company’s main pharmaceutical intermediates and API products and downstream end drugs (innovative drugs and generic drugs) is as follows:
Corresponding to the project name of innovative drugs and terminal drugs, corresponding to the product name / stage of intermediate API is generic drugs
Tigrelol, tigrelol intermediate TGA, tigrelol intermediate, tigrelol generic TGB, tigrelol intermediate TGC, etc
Tribetidine, tribetidine intermediate QBA, tribetidine intermediate tribetidine generic tribetidine injection QBB, etc
Badoxifen intermediate BDA, badoxifen intermediate BDA, badoxifen acetate imitation BDB, etc
Kapoterol intermediate kBb, kapoterol intermediate kapoterol ointment kapoterol KBC, kapoterol intermediate KBD and other kapoterol generic drugs / kapoterol liniments
Varenicline varenicline intermediate fla, varenicline intermediate varenicline raw material generic varenicline tablets FLC
Efrotinib intermediate nd403a efrotinib raw material innovative drug efrotinib mesylate tablets
Nd474 new drug intermediate nd474 – innovative drug approved for market
Nd407 new drug intermediate nd407a, new drug intermediate innovative drug application for listing nd407b
Nd582 new drug 582 project intermediate a, new drug 582 project – innovative drug clinical experiment intermediate B, new drug 582 project API
Intermediate a of nd522 new drug 522 project – clinical application of innovative drugs
The company uses the technology development platform and technical reserves to provide cdmo business of process research and development, small batch preparation, process optimization, scale-up production, registration and verification of batch production and commercial production of innovative drugs or generic drugs in combination with the needs of customers for APIs and intermediates in drug production. At the same time, at the stage of drug ind and anda registration and declaration, the technical services provided by the company to Chinese foreign pharmaceutical companies include API process research, quality research, stability research, declaration data writing and other CMC services required for registration and declaration. As of December 31, 2021, the company’s innovative drug cdmo has undertaken 173 projects, mainly in China, Japan, the United States and South Korea. The specific distribution is as follows:
No. total number of regions preclinical ~ phase I clinical phase II clinical phase III new drug listing application approved
1 China 109 96 4 5 2
2 Japan 47 41 3 1 0 2
3 Korea 8 4 1 1 1
4 United States
